164 related articles for article (PubMed ID: 21978107)
1. The economic disease burden of measles in Japan and a benefit cost analysis of vaccination, a retrospective study.
Takahashi K; Ohkusa Y; Kim JY
BMC Health Serv Res; 2011 Oct; 11():254. PubMed ID: 21978107
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
[TBL] [Abstract][Full Text] [Related]
3. [Costs and benefits of measles vaccination].
Ambrosch F; Wiedermann G; Harasek G
Fortschr Med; 1978 Feb; 96(8):409-14. PubMed ID: 415953
[TBL] [Abstract][Full Text] [Related]
4. Assessing the cost-effectiveness of different measles vaccination strategies for children in the Democratic Republic of Congo.
Doshi RH; Eckhoff P; Cheng A; Hoff NA; Mukadi P; Shidi C; Gerber S; Wemakoy EO; Muyembe-Tafum JJ; Kominski GF; Rimoin AW
Vaccine; 2017 Oct; 35(45):6187-6194. PubMed ID: 28966000
[TBL] [Abstract][Full Text] [Related]
5. Global eradication of measles: an epidemiologic and economic evaluation.
Levin A; Burgess C; Garrison LP; Bauch C; Babigumira J; Simons E; Dabbagh A
J Infect Dis; 2011 Jul; 204 Suppl 1():S98-106. PubMed ID: 21666220
[TBL] [Abstract][Full Text] [Related]
6. Economic analysis of the 1996-1997 mass measles immunization campaigns in South Africa.
Uzicanin A; Zhou F; Eggers R; Webb E; Strebel P
Vaccine; 2004 Sep; 22(25-26):3419-26. PubMed ID: 15308367
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of measles elimination in Latin America and the Caribbean: a prospective analysis.
Acharya A; Diaz-Ortega JL; Tambini G; de Quadros C; Arita I
Vaccine; 2002 Sep; 20(27-28):3332-41. PubMed ID: 12213403
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda.
Bishai D; Johns B; Nair D; Nabyonga-Orem J; Fiona-Makmot B; Simons E; Dabbagh A
J Infect Dis; 2011 Jul; 204 Suppl 1(Suppl 1):S107-15. PubMed ID: 21666151
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of measles outbreak intervention strategies.
Shiell A; Jorm LR; Carruthers R; Fitzsimmons GJ
Aust N Z J Public Health; 1998 Feb; 22(1):126-32. PubMed ID: 9599864
[TBL] [Abstract][Full Text] [Related]
10. An economic evaluation of the current measles vaccination program: A case study in Zhejiang Province, east China.
Zeng Y; Luo M; Chen J; He H; Deng X; Xie S; Fang Y
Vaccine; 2019 May; 37(23):3071-3077. PubMed ID: 31040084
[TBL] [Abstract][Full Text] [Related]
11. The average cost of measles cases and adverse events following vaccination in industrialised countries.
Carabin H; Edmunds WJ; Kou U; van den Hof S; Nguyen VH
BMC Public Health; 2002 Sep; 2():22. PubMed ID: 12241559
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of providing measles vaccination to all children in Guinea-Bissau.
Byberg S; Fisker AB; Thysen SM; Rodrigues A; Enemark U; Aaby P; Benn CS; Griffiths UK
Glob Health Action; 2017; 10(1):1329968. PubMed ID: 28580855
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of vaccination policies. The case of measles].
Lafarge H; Levy E; Rey M
Rev Epidemiol Sante Publique; 1985; 33(3):182-93. PubMed ID: 4081224
[TBL] [Abstract][Full Text] [Related]
14. Economic analysis of investment priorities for measles control.
Shepard DS
J Infect Dis; 1994 Nov; 170 Suppl 1():S56-62. PubMed ID: 7930754
[TBL] [Abstract][Full Text] [Related]
15. Measles control in developing and developed countries: the case for a two-dose policy.
Tulchinsky TH; Ginsberg GM; Abed Y; Angeles MT; Akukwe C; Bonn J
Bull World Health Organ; 1993; 71(1):93-103. PubMed ID: 8440043
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of options for measles vaccination strategy in a hypothetical Western European country.
Beutels P; Gay NJ
Epidemiol Infect; 2003 Apr; 130(2):273-83. PubMed ID: 12729196
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of second measles containing vaccine (MCV) dose: a systematic review of available evidence.
Bawa S; Wondimu A; Postma MJ; Hutubessy R; van Hulst M
Expert Rev Vaccines; 2024; 23(1):655-673. PubMed ID: 38924461
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of three different vaccination strategies against measles in Zambian children.
Dayan GH; Cairns L; Sangrujee N; Mtonga A; Nguyen V; Strebel P
Vaccine; 2004 Jan; 22(3-4):475-84. PubMed ID: 14670330
[TBL] [Abstract][Full Text] [Related]
19. Public Health and Economic Consequences of Vaccine Hesitancy for Measles in the United States.
Lo NC; Hotez PJ
JAMA Pediatr; 2017 Sep; 171(9):887-892. PubMed ID: 28738137
[TBL] [Abstract][Full Text] [Related]
20. Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis.
Zimmermann M; Frey K; Hagedorn B; Oteri AJ; Yahya A; Hamisu M; Mogekwu F; Shuaib F; McCarthy KA; Chabot-Couture G
Vaccine; 2019 Sep; 37(41):6039-6047. PubMed ID: 31471147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]